Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

June 2012

Clinical Trials, Cohort Studies, Pilot Studies

Proton Pump Inhibitors Increase the Incidence of Bone Fractures in Hepatitis C Patients. Mello M, Weideman RA, Little BB, et al. Dig Dis Sci. 2012 May 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22615013

A sustained virological response prevents development of insulin resistance in chronic hepatitis C patients. Aghemo A, Prati GM, Rumi MG, et al. Hepatology. 2012 May 22. doi: 10.1002/hep.25867. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22619107

Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/HIV Coinfection. Lo Re V 3rd, Volk J, Newcomb CW, et al. Hepatology. 2012 May 22. doi: 10.1002/hep.25866. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22619086

Refinement of stopping rules during treatment of hepatitis c-genotype 1 infection with boceprevir combined with peginterferon/ribavirin. Jacobson IM, Marcellin P, Zeuzem S, et al. Hepatology. 2012 May 22. doi: 10.1002/hep.25865. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22619063

Factors that Predict Response of Patients with HCV Infection to Boceprevir. Poordad F, Bronowicki JP, Gordon SC, et al. Gastroenterology. 2012 May 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22626609

strongest predictor of a SVR, regardless of polymorphisms in IL-28B. © 2012 AGA Institute.

Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C.

Imakiire K, Uto H, Sato Y, et al. Mol Med Report. 2012 May 21. doi: 10.3892/mmr.2012.924. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22614103

Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of

chronic hepatitis C patients. Lee SS, Roberts SK, Berak H, et al. Liver Int. 2012 May 24. doi: 10.1111/j.1478-3231.2012.02819.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22621707

Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. Stättermayer AF, Rutter K, Beinhardt S, et al. J Hepatol. 2012 May 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22634340

Impact of sirolimus and tacrolimus on mortality & graft loss in liver transplant recipients with and without HCV - an analysis of the SRTR database. Watt K, Dierkhising R, Heimbach J, Charlton M. Liver Transpl. 2012 May 29. doi: 10.1002/lt.23479. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22641474

Association of chronic hepatitis C with recurrent brief depression. Carta MG, Angst J, Moro MF, et al. J Affect Disord. 2012 May 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22609196

Treatment of Recurrent HCV Infection Following Liver Transplantation: Results of  a Multicenter, Randomized, versus placebo, Trial of ribavirin alone as maintenance therapy after one year of Peginterferon Alfa-2A plus Ribavirin. Calmus Y, Duvoux C, Pageaux G, et al. J Hepatol. 2012 May 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22613001

Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. Ogawa E, Furusyo N, Murata M, et al. J Hepatol. 2012 May 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22613000

Histological evolution of hepatitis C virus infection after renal transplantation.

de Oliveira Uehara SN, Emori CT, Pereira PD, et al. Clin Transplant. 2012 May 17. doi: 10.1111/j.1399-0012.2012.01635.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22594774

Correlation of viral load with bone marrow and hematological changes in pale patients with chronic hepatitis C virus. Abou El Azm AR, El-Bate H, et al. Arch Virol. 2012 May 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22569886

Prevalence of fibromyalgia among patients with chronic hepatitis C infection: relationship to viral characteristics and quality of life. Mohammad A, Carey JJ, Storan E, et al. J Clin Gastroenterol. 2012 May-Jun;46(5):407-12.

http://www.ncbi.nlm.nih.gov/pubmed/22499073

Treatment Results of Chronic Hepatitis C Genotype 5 and 6 Infections in Germany.

Mauss S, Berger F, Vogel M, Pfeiffer-Vornkahl H, Z et al. Gastroenterol. 2012 May;50(5):441-444. Epub 2012 May 11.

http://www.ncbi.nlm.nih.gov/pubmed/22581697

Basic and Applied Science, Pre-Clinical Studies

Sequential immunological analysis of HBV/HCV co-infected patients during

Peg-IFN/RBV therapy. Kondo Y, Ueno Y, Ninomiya M, et al. J Gastroenterol. 2012 May 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22588246

Preclinical Characterization of JTK-853, a Novel Non-nucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase. Ando I, Adachi T, Ogura N, et al. Antimicrob Agents Chemother. 2012 May 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22615294

MK-5172, a selective inhibitor of Hepatitis C Virus NS3/4a protease with broad activity across genotypes and resistant variants. Summa V, Ludmerer SW, McCauley JA, et al. Antimicrob Agents Chemother. 2012 May 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22615282

SKI-1/S1P inhibition: A promising surrogate to statins to block Hepatitis C virus  replication. Blanchet M, Seidah NG, Labonté P. Antiviral Res. 2012 May 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22626636

Chronic Hepatitis C Virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells. Roughan JE, Reardon KM, Cogburn KE, et al. Clin Vaccine Immunol. 2012 May 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22623650

Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics: Results of Computer-Based Simulations and a Clinical Drug-Drug Interaction Study. Reddy MB, Chen Y, Haznedar JO, et al. Clin Pharmacokinet. 2012 May 24. doi: 10.2165/11599700-000000000-00000. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22624502

Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a

Protease Inhibitor. Rong L, Ribeiro RM, Perelson AS. Bull Math Biol. 2012 May 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22639338

Population Pharmacokinetics and Pharmacodynamics of Ribavirin in Patients with

Chronic Hepatitis C Genotype 1 Infection. Jin R, Fossler MJ, McHutchison JG, Howell CD, Dowling TC. AAPS J. 2012 May 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22639111

The variable N terminal region of DDX5 contains structural elements and auto-inhibits its interaction with NS5B of hepatitis C virus. Dutta S, Gupta G, Choi YW, et al. Biochem J. 2012 May 28. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22640416

Liver X receptor α-mediated regulation of lipogenesis by core and NS5A proteins

contributes to HCV-induced liver steatosis and HCV replication. García-Mediavilla MV, Pisonero-Vaquero S, Lima-Cabello E, et al. Lab Invest. 2012 May 28. doi: 10.1038/labinvest.2012.88. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22641099

Hepatocytes that Express Variants of Cyclophilin A are Resistant to HCV Infection and Replication. von Hahn T, Schiene-Fischer C, Van ND, et al. Gastroenterology. 2012 May 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22580540

HIV/HCV Coinfection

Buprenorphine for Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Patients: Does It Serve as a Bridge to Hepatitis C Virus Therapy? Taylor LE, Maynard MA, Friedmann PD, et al. J Addict Med. 2012 May 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22614935

Sustained Virological Response to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus. Berenguer J, Rodríguez E, Miralles P, et al. Clin Infect Dis. 2012 May 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22610932

Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection. Grebely J, Hellard M, Applegate T, et al. AIDS. 2012 May 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22555168

Hepatitis C viral load, genotype 3 and IL28B CC genotype predict mortality in HIV and hepatitis C coinfected individuals. Clausen LN, Astvad K, Ladelund S, et al. AIDS. 2012 May 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22555162

Understanding the Behavioral Determinants of Retention in HIV Care: A Qualitative Evaluation of a Situated Information, Motivation, Behavioral Skills Model of Care Initiation and Maintenance. Smith LR, Fisher JD, Cunningham CO, Amico KR. AIDS Patient Care STDS. 2012 May 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22612447

Lower liver-related death in African American Women with HIV/HCV co-infection compared to caucasian and hispanic women. Sarkar M, Bacchetti P, French AL, et al. Hepatology. 2012 May 22. doi: 10.1002/hep.25859. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22618868

HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality. Klein M, Rollet K, Saeed S, et al. HIV Med. 2012 May 28. doi: 10.1111/j.1468-1293.2012.01028.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22639840

Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in US hospital discharge records: a cross-sectional study.  Nouraie M, Nekhai S, Gordeuk VR. Sex Transm Infect. 2012 May 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22628662

Cost-effective Screening for Acute Hepatitis C Virus Infection in HIV-Infected Men Who Have Sex With Men. Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Clin Infect Dis. 2012 May 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22491339

Chronic immune activation is a distinguishing feature of liver and PBMC gene signatures from HCV/HIV coinfected patients and may contribute to hepatic fibrogenesis.

Rasmussen AL, Wang IM, Shuhart MC, et al. Virology. 2012 May 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22608059

Hepatic Safety Profile of Fosamprenavir-Containing Regimens in HIV-1-Infected Patients With or Without Hepatitis B or C Coinfection. Ha B, Wine B, Rodriguez-Alcantra F, Shaefer M. HIV Clin Trials. 2012 May-Jun;13(3):171-7.

http://www.ncbi.nlm.nih.gov/pubmed/22592097

Complementary and Alternative Medicine

Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients. Farias MS, Budni P, Ribeiro CM, et al. Gastroenterol Hepatol. 2012 May 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22608494

Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as

predictors of antiviral response in chronic hepatitis C. Falleti E, Bitetto D, Fabris C, et al.

Hepatology. 2012 May 18. doi: 10.1002/hep.25848. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22610885

D-Livering The Message: The Importance of Vitamin D Status in Chronic Liver Disease. Kitson MT, Roberts SK. J Hepatol. 2012 May 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22634121

Recent Progress on Anti-Liver Fibrosis Candidates in Patents of Herbal Medicinal Products. Wang XB, Feng Y, Wang N, et al.  Recent Pat Food Nutr Agric. 2012 May 15. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22594662

Effect of soy protein supplementation in patients with chronic hepatitis C: A randomized clinical trial.

Oliveira LP, de Jesus RP, Boulhosa RS, et al. World J Gastroenterol. 2012 May 14;18(18):2203-11.

22611313

Epidemiology, Diagnostics, and Miscellaneous Works

Notes from the field : hepatitis C virus infections among young adults – rural Wisconsin, 2010. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2012 May 18;61:358.

http://www.ncbi.nlm.nih.gov/pubmed/22592276

Investigation of viral hepatitis infections possibly associated with health-care delivery - New York City, 2008-2011. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2012 May 18;61:333-8.

http://www.ncbi.nlm.nih.gov/pubmed/22592271

Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in HCV prevalence? Model projections for different epidemic settings. Vickerman P, Martin N, Turner K, Hickman M. Addiction. 2012 May 7. doi: 10.1111/j.1360-0443.2012.03932.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22564041

The burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes. Dacosta Dibonaventura M, Yuan Y, Wagner JS, et al. Eur J Gastroenterol Hepatol. 2012 May 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22617367

Colonial history and contemporary transmission shape the genetic diversity of hepatitis C virus genotype 2 in Amsterdam. Markov PV, van de Laar TJ, Thomas XV, et al. J Virol. 2012 May 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22573865

Hepatitis C prevalence in injecting drug users in Europe, 1990-2007: Impact of study recruitment setting. Rondy M, Wiessing L, Hutchinson SJ, et al. Epidemiol Infect. 2012 May 17:1-10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22595549

Hepatitis C Virus in Arab World: A State of Concern.

Daw MA, Dau AA. ScientificWorldJournal. 2012;2012:719494. Epub 2012 May 2.

http://www.ncbi.nlm.nih.gov/pubmed/22629189

Blood transfusion practice in a rural hospital in Northern Ghana, Damongo, West Gonja District. Kubio C, Tierney G, Quaye T, et al. Transfusion. 2012 May 21. doi: 10.1111/j.1537-2995.2012.03709.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22612858

Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Treloar C, Hull P, Dore GJ, Grebely J. Drug Alcohol Rev. 2012 May 21. doi: 10.1111/j.1465-3362.2012.00468.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22612899

Provider and Patient Correlates of Provider Decisions to Recommend HCV Treatment

to HIV Co-Infected Patients. Wagner G, Osilla KC, Garnett J, et al. J Int Assoc Physicians AIDS Care (Chic). 2012 May 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22564797

Male IDUs who have sex with men in England, Wales and Northern Ireland: are they at greater risk of bloodborne virus infection and harm than those who only have sex with women? Marongiu A, Hope VD, Parry JV, Ncube F. Sex Transm Infect. 2012 May 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22628667

New antiviral therapies in the management of HCV infection. Farnik H, Zeuzem S.

Antivir Ther. 2012 May 25. doi: 10.3851/IMP2127. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22626842

The National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): Twenty Years of Research to Advance Blood Product Safety and Availability. Kleinman S, King MR, Busch MP, et al. Transfus Med Rev. 2012 May 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22633182

Evaluation of MR imaging with T1 and T2* mapping for the determination of hepatic

iron overload. Henninger B, Kremser C, Rauch S, et al. Eur Radiol. 2012 May 30. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22645044

Utilization of hepatitis C antibody-positive livers: genotype dominance is virally  determined. O'Leary JG, Neri MA, Trotter JF, et al. Transpl Int. 2012 May 30. doi: 10.1111/j.1432-2277.2012.01498.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22643162

Hepatitis C transmission due to contamination of multidose medication vials: Summary of an outbreak and a call to action. Branch-Elliman W, Weiss D, Balter S, Bornschlegel K, Phillips M. Am J Infect Control. 2012 May 25. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22632822

Impact of disease severity on health care costs in patients with chronic hepatitis C (CHC) virus infection.Gordon S, Pockros P, Terrault N, et al.  Hepatology. 2012 May 18. doi: 10.1002/hep.25842. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22610658

Evolution of hepatitis C virus hypervariable region 1 in chronically infected children.

Jackowiak P, Kowala-Piaskowska A, Figlerowicz M, et al. Virus Res. 2012 May 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22610132

Structured Information Exchange on Infectious Diseases for Prisoners.

Flühmann P, Wassmer M, Schwendimann R. J Correct Health Care. 2012 May 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22569902

Impact of Donor Hepatitis C Virus Infection Status on Death and Need for Liver

Transplant in Hepatitis C Virus-Positive Kidney Transplant Recipients. Kucirka LM, Peters TG, Segev DL. Am J Kidney Dis. 2012 May 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22560841

Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA. Jewett A, Smith BD, Garfein RS, et al. J Clin Virol. 2012 May 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22560051

Liver Cancer

Guideline on the use of new anticancer drugs for the treatment of Hepatocellular

Carcinoma 2010 update. Kaneko S, Furuse J, Kudo M, et al.Hepatol Res. 2012 Jun;42(6):523-542. doi: 10.1111/j.1872-034X.2012.00981.x.

http://www.ncbi.nlm.nih.gov/pubmed/22568457

Does transient elastography (FibroScan(®) ) have a role in decision making in hepatocellular carcinoma? Pesce A, Scilletta R, Branca A, et al. HPB (Oxford). 2012 Jun;14(6):403-8. doi: 10.1111/j.1477-2574.2012.00465.x. Epub

2012 Mar 28.

http://www.ncbi.nlm.nih.gov/pubmed/22568417

Is Serum Alpha-Fetoprotein Useful for Predicting Recurrence and Mortality Specific to Hepatocellular Carcinoma After Hepatectomy? A Test Based on Propensity Scores and Competing Risks Analysis. Shim JH, Yoon DL, Han S, et al. Ann Surg Oncol. 2012 May 30. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22644512

Role of Operative Therapy in Non-cirrhotic Patients with Metastatic

Hepatocellular Carcinoma. Zaydfudim V, Smoot RL, Clark CJ, et al. J Gastrointest Surg. 2012 May 30. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22644447

Hepatic arterial embolization for unresectable hepatocellular carcinomas: do

technical factors affect prognosis? Yamakado K, Miyayama S, Hirota S, et al.

Jpn J Radiol. 2012 May 30. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22644412

Hepatic artery injection of (131)I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study. Wu L, Yang YF, Ge NJ, et al. Eur J Nucl Med Mol Imaging. 2012 May 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22588627

Growth arrest-specific homeobox is associated with poor survival in patients with hepatocellular carcinoma. Zhou P, Chen Z, Chang RM, et al. Med Oncol. 2012 May 27. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22644917

Bevacizumab and Erlotinib in Previously Untreated Inoperable and Metastatic

Hepatocellular Carcinoma. Govindarajan R, Siegel E, Makhoul I, Williamson S. Am J Clin Oncol. 2012 May 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22643560

Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma. Shau WY, Shao YY, Yeh YC, et al. Oncologist. 2012 May 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22622151

Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in

vitro and in vivo. Wang L, Jia D, Duan F, et al. Biochem Biophys Res Commun. 2012 May 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22634008

Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular

Carcinoma: Five-Year Survival Analysis. Malagari K, Pomoni M, Moschouris H, et al. Cardiovasc Intervent Radiol. 2012 May 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22614031

A Randomized Controlled Trial of Radiofrequency Ablation and Surgical Resection in the Treatment of Small Hepatocellular Carcinoma. Feng K, Yan J, Li X, J et al. Hepatol. 2012 May 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22634125

Liver Transplantation for Hepatocellular Carcinoma: Long-Term Results Suggest Excellent Outcomes. Doyle MB, Vachharajani N, Maynard E, et al. J Am Coll Surg. 2012 May 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22608403

Efficacy of Laparoscopic Surgery for Recurrent Hepatocellular Carcinoma.

Et al.  J, Tamura A, Kaneko H. Hepatogastroenterology. 2012 May 16;59(117). doi: 10.5754/hge12302. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22591625